Sustained secretion of anti ‐TNF alpha monoclonal antibody from ex‐vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis

ConclusionsThis work demonstrates micro dermal tissues engineered to secrete active adalimumab as a proof of concept for antibody sustained secretion from the novel ex‐vivo gene therapy TARGT platform. This technology may now be applied to a range of antibodies for the therapy of other diseases.

Source: The Journal of Gene Medicine - May 1, 2017 Category: Genetics & Stem Cells Authors: Inbal Zafir ‐Lavie, Reem Miari, Shay Sherbo, Simi Krispel, Osnat Tal, Atar Liran, Tamar Shatil, Felix Badinter, Haim Goltsman, Nir Shapir, Itai Benhar, Garry A. Neil, Amos Panet Tags: RESEARCH ARTICLE Source Type: research